US45674E1091 - Common Stock
IN8BIO INC
NASDAQ:INAB (5/15/2024, 7:00:03 PM)
After market: 1.1111 -0.02 (-1.67%)1.13
+0.09 (+8.65%)
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 26 full-time employees. The company went IPO on 2020-11-12. The company is focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead product candidates are in Phase 1 clinical trials: INB-200, for the treatment of patients with newly diagnosed glioblastoma (GBM), and INB-100, for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation. The company is also focused on patient enrollment in the Company-sponsored Phase 2 clinical trial of INB-400 in which autologous genetically modified gamma-delta T cells will be assessed in newly diagnosed GBM patients. Its DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing GBM and other solid tumor types.
IN8BIO INC
Empire State Building, 350 5Th Avenue, Suite 5330
New York City NEW YORK
P: 16466006438
CEO: William Ho
Employees: 26
Website: https://www.in8bio.com
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress...
INAB stock results show that IN8bio missed analyst estimates for earnings per share the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips IN8bio (NASDAQ:INAB) just reported results for the first quarter of 2024.IN8bio...
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights ...
Here you can normally see the latest stock twits on INAB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: